Inhibitor Therapeutics: Director Departs, New Director Appointed
Ticker: INTI · Form: 8-K · Filed: Oct 27, 2025 · CIK: 1042418
| Field | Detail |
|---|---|
| Company | Inhibitor Therapeutics, Inc. (INTI) |
| Form Type | 8-K |
| Filed Date | Oct 27, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, material-agreement
TL;DR
Board shakeup at Inhibitor Therapeutics: Lerner out, Johnson in. Material agreement signed.
AI Summary
On October 24, 2025, Inhibitor Therapeutics, Inc. reported the departure of Director Dr. David M. Lerner and the appointment of Dr. Robert L. Johnson as a new director. The company also announced a material definitive agreement, though details are not provided in this excerpt. The filing also mentions compensatory arrangements for certain officers.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, while material definitive agreements are crucial for understanding future business operations.
Risk Assessment
Risk Level: medium — The filing indicates changes in directorship and a material definitive agreement, which could have significant implications for the company's future direction and financial performance.
Key Players & Entities
- Inhibitor Therapeutics, Inc. (company) — Registrant
- Dr. David M. Lerner (person) — Departing Director
- Dr. Robert L. Johnson (person) — Appointed Director
- October 24, 2025 (date) — Report Date
- October 21, 2025 (date) — Earliest Event Reported
FAQ
Who has been appointed as a new director to the board of Inhibitor Therapeutics, Inc.?
Dr. Robert L. Johnson has been appointed as a new director.
Which director has departed from Inhibitor Therapeutics, Inc.?
Dr. David M. Lerner has departed from the board.
What is the earliest event date reported in this 8-K filing?
The earliest event reported is October 21, 2025.
What is the filing date of this 8-K report?
The report is filed as of October 27, 2025, with the earliest event reported on October 21, 2025.
What type of agreement is mentioned in the filing?
A material definitive agreement is mentioned.
Filing Stats: 986 words · 4 min read · ~3 pages · Grade level 12.6 · Accepted 2025-10-24 20:34:19
Filing Documents
- form8-k.htm (8-K) — 49KB
- ex10-1.htm (EX-10.1) — 107KB
- ex10-2.htm (EX-10.2) — 271KB
- 0001493152-25-019381.txt ( ) — 637KB
- inti-20251024.xsd (EX-101.SCH) — 3KB
- inti-20251024_lab.xml (EX-101.LAB) — 33KB
- inti-20251024_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) The following exhibit is filed with this report. Exhibit No. Description of Exhibit 10.1+ Master Services Agreement, dated October 21, 2025 10.2 Inhibitor Therapeutics, Inc. 2025 Equity Incentive Plan 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). + Certain personally identifiable information has been omitted from this exhibit pursuant to Item 601(a)(6) of Regulation S-K.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 24, 2025 INHIBITOR THERAPEUTICS, INC. By: /s/ Francis E. O'Donnell Name: Francis E. O'Donnell Title: Executive Chairman and CEO